PARP1 and neoplasm: From the in vivo studies using EAC-mice, the CDA-dextran conjugates displayed a higher anticancer activity as revealed from the EAC tumor size, weight, and biochemical markers Caspase-independent apoptotic markers PARP-1 and AIF.